Results 11 to 20 of about 36,516 (242)

EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression

eLife, 2023
Chondrosarcomas are primary cancers of cartilaginous tissue and capable of alteration to highly aggressive, metastatic, and treatment-refractory states, leading to a poor prognosis with a five-year survival rate at 11 months for dedifferentiated subtype.
Zong-Shin Lin, Chiao-Chen Chung, Yu-Chia Liu, Chu-Han Chang, Hui-Chia Liu, Yung-Yi Liang, Teng-Le Huang, Tsung-Ming Chen, Che-Hsin Lee, Chih-Hsin Tang, Mien-Chie Hung, Ya-Huey Chen   +11 more
doaj   +1 more source

Classification of Chondrosarcoma: From Characteristic to Challenging Imaging Findings

Cancers, 2023
Simple Summary Chondrosarcomas are a very heterogeneous group of cartilage-forming tumors that comprise approximately one-third of all malignant bone tumors.
Jun-Ho Kim, S. Lee
semanticscholar   +1 more source

Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions

Cancers, 2023
Simple Summary This review article aims in describing the origins of chondrosarcoma radiation-resistance and proposes several potential solutions in order to improve the treatment, in regard with tumor grade and characteristics.
Antoine Gilbert, M. Tudor, Juliette Montanari, Kevin Commenchail, D. Savu, P. Lesueur, François Chevalier   +6 more
semanticscholar   +1 more source

High-Resolution Secretome Analysis of Chemical Hypoxia Treated Cells Identifies Putative Biomarkers of Chondrosarcoma

Proteomes, 2022
Chondrosarcoma is the second most common bone tumor, accounting for 20% of all cases. Little is known about the pathology and molecular mechanisms involved in the development and in the metastatic process of chondrosarcoma. As a consequence, there are no
Donatella Pia Spanò, Simone Bonelli, Matteo Calligaris, Anna Paola Carreca, Claudia Carcione, Giovanni Zito, Aldo Nicosia, Sergio Rizzo, Simone Dario Scilabra   +8 more
doaj   +1 more source

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Clinical Cancer Research, 2023
Purpose: Patients with unresectable/metastatic chondrosarcoma have poor prognoses; conventional chondrosarcoma is associated with a median progression-free survival (PFS) of
V. Subbiah, S. Chawla, A. Conley, B. Wilky, A. Tolcher, N. Lakhani, D. Berz, V. Andrianov, W. Crago, Monica Holcomb, Abrahim Hussain, C. Veldstra, J. Kalabus, Brianne O'Neill, Lane Senne, Emily Rowell, Analeah B Heidt, K. Willis, Brendan P Eckelman   +18 more
semanticscholar   +1 more source

Mice with Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma via overactivation of YAP signaling

Cell Death and Disease, 2022
Chondrosarcoma (CHS) is a rare type of soft sarcoma with increased production of cartilage matrix arising from soft bone tissues. Currently, surgical resection is the primary clinical treatment for chondrosarcoma due to the poor response to radiotherapy ...
Yang Li, Shuting Yang, Yang Liu, Shuying Yang   +3 more
doaj   +1 more source

Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma

Cancer Research Communications, 2023
Dedifferentiated chondrosarcoma (DDCS) is a rare high-grade chondrosarcoma characterized by a well-differentiated chondrosarcoma (WDCS) component that abruptly transitions to a high-grade, noncartilaginous sarcomatous component.
J. Dermawan, K. Nafa, A. Mohanty, Yingjuan Xu, I. Rijo, J. Casanova, L. Villafania, J. Benhamida, C. Kelly, W. Tap, P. Boland, N. Fabbri, J. Healey, M. Ladanyi, Chao Lu, M. Hameed   +15 more
semanticscholar   +1 more source

Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options

International Journal of Molecular Sciences, 2023
This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS), including grade 2–3 conventional, dedifferentiated, and mesenchymal CS. The diagnosis
C. Tlemsani, F. Larousserie, S. de Percin, V. Audard, D. Hadjadj, Jeanne M Chen, D. Biau, P. Anract, B. Terris, F. Goldwasser, É. Pasmant, P. Boudou-Rouquette   +11 more
semanticscholar   +1 more source

Visfatin-Induced Inhibition of miR-1264 Facilitates PDGF-C Synthesis in Chondrosarcoma Cells and Enhances Endothelial Progenitor Cell Angiogenesis

Cells, 2022
New treatments for chondrosarcoma are extremely important. Chondrosarcoma is a primary malignant bone tumor with a very unfavorable prognosis. High-grade chondrosarcoma has a high potential to metastasize to any organ in the body. Platelet-derived growth
Chang-Yu Song, Sunny Li-Yun Chang, Chih-Yang Lin, Chun-Hao Tsai, Shang-Yu Yang, Yi-Chin Fong, Yu-Wen Huang, Shih-Wei Wang, Wei-Cheng Chen, Chih-Hsin Tang   +9 more
doaj   +1 more source

Mesenchymal chondrosarcoma of the mandible: A case report

Journal of Craniomaxillofacial Research, 2021
Mesenchymal chondrosarcoma as an aggressive type of chondrosarcoma shows a characteristic biphasic histopathologic pattern. The head and neck region is included a high proportion of extra skeletal sites. Very rare examples of Mesenchymal Chondrosarcoma
Samira Derakhshan, Sedigheh Rahrotaban, Samaneh Shirani, Shima Abbasi   +3 more
doaj   +1 more source